Go Pro
NASDAQ:SCNX

Scienture Q1 2026 Earnings Report

Scienture logo
$0.29 -0.02 (-6.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.28 -0.01 (-2.84%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Scienture Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.40 million
Beat/Miss
Missed by -$344.68 thousand
YoY Revenue Growth
N/A

Scienture Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Friday, May 15, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Scienture's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Scienture Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Tvardi Therapeutics (NASDAQ:TVRD) & Scienture (NASDAQ:SCNX) Head-To-Head Survey
See More Scienture Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email.

About Scienture

Scienture (NASDAQ:SCNX) is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD). ONYDA XR is designed as a liquid formulation and may be used alone or in combination with stimulant ADHD medications, providing an option for patients who have difficulty swallowing tablets or who require a non-stimulant therapy.

The company is focused primarily on the U.S. pharmaceutical market, where it seeks to expand access to its products through commercialization, partnerships and further product development. Scienture’s portfolio and pipeline are directed toward specialty-care opportunities in which formulation, dosing flexibility or other product characteristics can provide a meaningful clinical benefit.

View Scienture Profile